{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T01:26:54Z","timestamp":1786670814802,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272035"],"award-info":[{"award-number":["82272035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20465"],"award-info":[{"award-number":["U23A20465"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["12275057"],"award-info":[{"award-number":["12275057"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"DOI":"10.1007\/s00259-026-08097-6","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:29:54Z","timestamp":1786667394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["68Ga-granzyme B (68Ga-NOTA-GSI) PET\/CT for predicting immunotherapy response and progression free survival in NSCLC"],"prefix":"10.1007","author":[{"given":"Ziyi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihuang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-7522","authenticated-orcid":false,"given":"Shaoli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"8097_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"8097_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41571-019-0293-2","volume":"17","author":"JA Clara","year":"2020","unstructured":"Clara JA, Monge C, Yang Y, Takebe N. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat Rev Clin Oncol. 2020;17:204\u201332.","journal-title":"Nat Rev Clin Oncol"},{"key":"8097_CR3","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1002\/cncr.34977","volume":"129","author":"JW Carlisle","year":"2023","unstructured":"Carlisle JW, Leal T. Advancing immunotherapy in small cell lung cancer. Cancer. 2023;129:3525\u201334.","journal-title":"Cancer"},{"key":"8097_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","volume":"17","author":"W Cheng","year":"2024","unstructured":"Cheng W, Kang K, Zhao A, Wu Y. Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol. 2024;17:54.","journal-title":"J Hematol Oncol"},{"key":"8097_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ccell.2024.01.010","volume":"42","author":"BY Nabet","year":"2024","unstructured":"Nabet BY, Hamidi H, Lee MC, et al. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell. 2024;42:429\u2013e443424.","journal-title":"Cancer Cell"},{"key":"8097_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1148\/radiol.210518","volume":"306","author":"L Dercle","year":"2023","unstructured":"Dercle L, Sun S, Seban RD, et al. Emerging and Evolving Concepts in Cancer Immunotherapy Imaging. Radiology. 2023;306:32\u201346.","journal-title":"Radiology"},{"key":"8097_CR7","doi-asserted-by":"crossref","unstructured":"de Groot DJA, Lub-de Hooge MN, van Meerten T, Brouwers AH, de Vries EGE. Facts and hopes for PET imaging-derived immunotherapy biomarkers. Clin Cancer Res. 2024;30:5252\u20135259.","DOI":"10.1158\/1078-0432.CCR-24-1427"},{"key":"8097_CR8","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1007\/s00259-024-06794-8","volume":"51","author":"M Masse","year":"2024","unstructured":"Masse M, Chardin D, Tricarico P, et al. [(18)F]FDG-PET\/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal. Eur J Nucl Med Mol Imaging. 2024;51:3696\u2013708.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8097_CR9","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/s41591-022-02084-8","volume":"28","author":"L Kist de Ruijter","year":"2022","unstructured":"Kist de Ruijter L, van de Donk PP, Hooiveld-Noeken JS, et al. Whole-body CD8(+) T cell visualization before and during cancer immunotherapy: a phase 1\/2 trial. Nat Med. 2022;28:2601\u201310.","journal-title":"Nat Med"},{"key":"8097_CR10","first-page":"686","volume":"63","author":"J Smit","year":"2022","unstructured":"Smit J, Borm FJ, Niemeijer AN, et al. PD-L1 PET\/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer. J Nucl Med. 2022;63:686\u201393.","journal-title":"J Nucl Med"},{"key":"8097_CR11","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1007\/s00259-021-05407-y","volume":"48","author":"PP van de Donk","year":"2021","unstructured":"van de Donk PP, Wind TT, Hooiveld-Noeken JS, et al. Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. Eur J Nucl Med Mol Imaging. 2021;48:4369\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8097_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41467-020-20604-3","volume":"12","author":"S Hiroyasu","year":"2021","unstructured":"Hiroyasu S, Zeglinski MR, Zhao H, et al. Granzyme B inhibition reduces disease severity in autoimmune blistering diseases. Nat Commun. 2021;12:302.","journal-title":"Nat Commun"},{"key":"8097_CR13","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","volume":"621","author":"XQ Wang","year":"2023","unstructured":"Wang XQ, Danenberg E, Huang CS, et al. Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature. 2023;621:868\u201376.","journal-title":"Nature"},{"key":"8097_CR14","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1158\/0008-5472.CAN-16-3346","volume":"77","author":"BM Larimer","year":"2017","unstructured":"Larimer BM, Wehrenberg-Klee E, Dubois F, et al. Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. Cancer Res. 2017;77:2318\u201327.","journal-title":"Cancer Res"},{"key":"8097_CR15","doi-asserted-by":"crossref","unstructured":"Zhou H, Wang Y, Xu H et al. Noninvasive interrogation of CD8\u2009+\u2009T cell effector function for monitoring early tumor responses to immunotherapy. J Clin Invest. 2022;132:e161065.","DOI":"10.1172\/JCI161065"},{"key":"8097_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00259-022-05986-4","volume":"50","author":"C Jiang","year":"2023","unstructured":"Jiang C, Tian Q, Xu X, et al. Enhanced antitumor immune responses via a new agent [(131)I]-labeled dual-target immunosuppressant. Eur J Nucl Med Mol Imaging. 2023;50:275\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8097_CR17","doi-asserted-by":"crossref","unstructured":"Liu Q, Xu X, Yang Z et al. Granzyme B PET\/CT Imaging Evaluates Early Response to Immunotherapy in Gastric Cancer. J Nucl Med. 2024;65:1695-1701.","DOI":"10.2967\/jnumed.124.267529"},{"key":"8097_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri A, Maji A, Potdar PD, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22:40.","journal-title":"Mol Cancer"},{"key":"8097_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nri819","volume":"2","author":"M Barry","year":"2002","unstructured":"Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol. 2002;2:401\u20139.","journal-title":"Nat Rev Immunol"},{"key":"8097_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16:151\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"8097_CR21","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1158\/1078-0432.CCR-18-2407","volume":"25","author":"BM Larimer","year":"2019","unstructured":"Larimer BM, Bloch E, Nesti S, et al. The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. Clin Cancer Res. 2019;25:1196\u2013205.","journal-title":"Clin Cancer Res"},{"key":"8097_CR22","doi-asserted-by":"publisher","first-page":"8791","DOI":"10.1038\/s41467-024-53197-2","volume":"15","author":"X Shen","year":"2024","unstructured":"Shen X, Zhou H, Zhou X, et al. (68)Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1\/2 clinical trial. Nat Commun. 2024;15:8791.","journal-title":"Nat Commun"},{"key":"8097_CR23","doi-asserted-by":"publisher","first-page":"e2102500","DOI":"10.1002\/advs.202102500","volume":"8","author":"C Jiang","year":"2021","unstructured":"Jiang C, Zhang L, Xu X, et al. Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD-L1 and CTLA-4. Adv Sci (Weinh). 2021;8:e2102500.","journal-title":"Adv Sci (Weinh)"},{"key":"8097_CR24","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412\u201320.","journal-title":"Clin Cancer Res"},{"key":"8097_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41422-020-0379-5","volume":"30","author":"JA Shyer","year":"2020","unstructured":"Shyer JA, Flavell RA, Bailis W. Metabolic signaling in T cells. Cell Res. 2020;30:649\u201359.","journal-title":"Cell Res"},{"key":"8097_CR26","doi-asserted-by":"publisher","first-page":"100644","DOI":"10.1016\/j.drup.2019.100644","volume":"46","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Wever B, Mazzaschi G, et al. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resist Updat. 2019;46:100644.","journal-title":"Drug Resist Updat"},{"key":"8097_CR27","doi-asserted-by":"publisher","first-page":"7175","DOI":"10.1158\/1078-0432.CCR-19-0433","volume":"25","author":"DA Schaer","year":"2019","unstructured":"Schaer DA, Geeganage S, Amaladas N, et al. The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy. Clin Cancer Res. 2019;25:7175\u201388.","journal-title":"Clin Cancer Res"},{"key":"8097_CR28","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378:2078\u201392.","journal-title":"N Engl J Med"},{"key":"8097_CR29","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non\u2013Small-Cell Lung Cancer. N Engl J Med. 2018;379:2040\u201351.","journal-title":"N Engl J Med"},{"key":"8097_CR30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu T-E, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:198\u2013211.","journal-title":"Lancet Oncol"},{"key":"8097_CR31","first-page":"e003956add00395","volume":"13","author":"Addendum 1","year":"2025","unstructured":"Addendum 1. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. J Immunother Cancer. 2025;13:e003956add003951.","journal-title":"J Immunother Cancer"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08097-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08097-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08097-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:29:56Z","timestamp":1786667396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08097-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":31,"alternative-id":["8097"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08097-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The prospective study was approved by the Ethics Committee of Fudan University Shanghai Cancer Center (No.2201249-28) and registered online in the Chinese Clinical Trials Registry (ChiCTR2200062089). Registered 21 July 2022.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a0\n                      \n                      .","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}